REVELATION BIOSCIENCES, INC.

(REVB)
  Reporte
Diferido Nasdaq  -  22:00 24/06/2022
0.4900 USD   -6.26%
13/06Revelation Biosciences completa la inscripción y la dosificación del estudio de fase 1b del tratamiento de la rinitis alérgica
MT
13/06Revelation Biosciences Inc. Anuncia la finalización de la dosificación de un estudio clínico de fase 1b CLEAR de REVTx-99b para el tratamiento de la rinitis alérgica
CI
31/05Revelation Biosciences, Inc. El auditor plantea dudas sobre la "empresa en funcionamiento
CI
ResumenCotizacionesGráficosNoticiasRatingsAgendaEmpresaFinanzasConsensoRevisionesDerivados 
ResumenTodasOtros idiomasComunicadosPubls. oficialesNoticias del sector
Noticias en otros idiomas sobre REVELATION BIOSCIENCES, INC.
13/06Revelation Biosciences Completes Enrollment, Dosing of Phase 1b Study of Allergic Rhini..
13/06Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinica..
13/06Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinica..
13/06Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinica..
10/06REVELATION BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listi..
31/05REVELATION BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continued Listi..
31/05Revelation Biosciences, Inc. Auditor Raises 'Going Concern' Doubt
23/05Revelation Biosciences Says Safety Monitoring Committee Recommends Continuation of Tria..
23/05Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Co..
23/05Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Co..
23/05Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Co..
16/05Earnings Flash (REVB) REVELATION BIOSCIENCES Reports Q1 Loss $-0.47
16/05Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended Marc..
16/05Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March..
16/05REVELATION BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Conditi..
06/05REVELATION BIOSCIENCES, INC. : Changes in Registrant's Certifying Accountant, Financial St..
22/04REVELATION BIOSCIENCES, INC. Financial Statements and Exhibits (form 8-K/A)
15/04REVELATION BIOSCIENCES : REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Form 8-..
15/04REVELATION BIOSCIENCES, INC. Financial Statements and Exhibits (form 8-K/A)
15/04REVELATION BIOSCIENCES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
15/04Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December ..
06/04Revelation Biosciences Inc. Announces Conference Call to Provide a Corporate Update
30/03SECTOR UPDATE : Health Care Stocks Close Slightly Lower
30/03SECTOR UPDATE : Health Care
30/03Top Midday Decliners
30/03Revelation Biosciences Says Mid-Stage Trial of Preventive Treatment for Influenza A Mis..
30/03Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Chal..
30/03Revelation Biosciences Inc. Announces Primary Endpoint Analysis for Phase 2b Viral Chal..
24/03Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b..
24/03Revelation Biosciences Inc. Outlines Details on the Upcoming Data Analysis for Phase 2b..
22/03Revelation Biosciences Inc. to Present at the 2022 Virtual Growth Conference Presented ..
21/03REVELATION BIOSCIENCES, INC.(NASDAQC : REVB) added to S&P TMI Index
15/03SECTOR UPDATE : Health Care Stocks Gaining Steam in Late Trade
15/03SECTOR UPDATE : Health Care
15/03REVELATION BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
15/03Top Midday Gainers
15/03Revelation Biosciences Completes Dosing in Trial to Prevent Influenza A Infections; Sha..
15/03Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2b Viral..
15/03Revelation Biosciences Inc. Announces Enrollment and Dosing Complete for Phase 2B Viral..
15/03REVELATION BIOSCIENCES : Announces Enrollment and Dosing Complete for Phase 2b Viral Chall..
08/03Revelation Biosciences Inc. to Present at the 34th Annual Roth Conference
23/02Top Premarket Gainers
11/02REVELATION BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
07/02Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor Conference
31/01Revelation Biosciences, Inc. announced that it has received $7.598001 million in fundin..
27/01REVELATION BIOSCIENCES : Raises $7.76 Million in Equity Financing - Form 8-K
27/01REVELATION BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
24/01Revelation Biosciences Signs Deal With Unnamed Investor for $7.8 Million Private Placem..
24/01Revelation Biosciences Raises $7.76 Million in Equity Financing
23/01Revelation Biosciences, Inc. announced that it expects to receive $7.598001 million in ..
20/01Revelation Biosciences Doses First Patients in Study of H3N2 Influenza Treatment; Share..
20/01Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral C..
20/01Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2B Viral C..
18/01Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clin..
18/01Revelation Biosciences Inc. Announces Enroll and Dose First Patient in Phase 1b Clinica..
14/01REVELATION BIOSCIENCES : UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INF..
14/01REVELATION BIOSCIENCES, INC. : Completion of Acquisition or Disposition of Assets, Changes..
13/01REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro An..
12/01REVELATION BIOSCIENCES, INC.(NASDAQC : REVB) added to NASDAQ Composite Index
11/01REVELATION BIOSCIENCES : Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activit..
2021Revelation Biosciences, Inc. Reports Earnings Results for the Nine Months Ended Septemb..